As the most prestigious meeting for GI professionals, there’s no better place to showcase your findings than Digestive Disease Week® (DDW). By submitting an abstract for consideration at DDW 2022, you’ll contribute your voice to the conversations that propel progress and gain valuable feedback from peers.
Don’t miss this opportunity to present your research to an audience of forward-thinking leaders and gain exposure on a global scale. In addition to presentation, accepted abstracts will be published in online supplements to Gastroenterology or GIE: Gastrointestinal Endoscopy, two of the top GI journals in the field. The deadline to submit an abstract is Thursday, Dec. 2, 2021, at 21:00 Eastern time (UTC -5).
Submission Resources
Visit the DDW website for helpful submission resources, including tutorial videos, submission guidelines and abstract categories. We’ll also be posting tips and tricks on DDW News. Once you submit, share the exciting news using this social badge, and don’t forget to tag us @AmerGastroAssn.
Abstract Presentation
DDW will offer in person and virtual presentation options for the 2022 meeting. Abstracts submitted for oral or poster presentation will be considered for presentation on-site in San Diego, CA; presenters will be required to attend in person. Please be advised that all DDW attendees and presenters will be required to provide proof of COVID vaccination to attend. Authors unable to attend DDW in San Diego can select the ePoster only presentation option, which will be considered for electronic presentation at the DDW ePosters site.
AGA Abstract Descriptors
In an effort to help match your abstract(s) to the best descriptor for submission, the AGA Institute Council has provided an expanded descriptor document as to what the abstract review committee is looking for in submitted abstracts. Please use this to submit your abstract to the most appropriate section and descriptor. Featured new descriptors include:
- COVID and Clinical Practice
- IBD: Omics for Prognosis, Therapeutic Selection, and Mechanisms
- Phase 2 and 3 Microbial Therapies for IBD
- Health Disparities in Patients with GI Disease
- Issues of Provider Diversity, Equity and Inclusion in GI
